Impaired Pulmonary Diffusion in Heart Failure With Preserved Ejection Fraction
Mini-Focus Issue: Reduced, Preserved, and Borderline Ejection Fraction
Abstract
Objectives:
The purpose of this study was to compare measures of gas exchange at rest and during exercise in patients with heart failure and preserved ejection fraction (HFpEF) with age- and sex-matched control subjects.
Background:
Patients with HFpEF display elevation in left heart pressures, but it is unclear how this affects pulmonary gas transfer or its determinants at rest and during exercise.
Methods:
Patients with HFpEF (n = 20) and control subjects (n = 26) completed a recumbent cycle ergometry exercise test with simultaneous measurement of ventilation and gas exchange. Diffusion of the lungs for carbon monoxide (DLCO) and its subcomponents, pulmonary capillary blood volume (VC) and alveolar-capillary membrane conductance (DM), were measured at rest, and matched for low-intensity (20 W) and peak exercise. Stroke volume was measured by transthoracic echocardiography to calculate cardiac output.
Results:
Compared with control subjects, patients with HFpEF displayed impaired diastolic function and reduced exercise capacity. Patients with HFpEF demonstrated a 24% lower DLCO at rest (11.0 ± 2.3 ml/mm Hg/min vs. 14.4 ± 3.3 ml/mm Hg/min; p < 0.01) related to reductions in both DM (18.1 ± 4.9 ml/mm Hg/min vs. 23.1 ± 9.1 ml/mm Hg/min; p = 0.04), and VC (45.9 ± 15.2. ml vs. 58.9 ± 16.2 ml; p = 0.01). DLCO was lower in patients with HFpEF compared with control subjects in all stages of exercise, yet its determinants showed variable responses. With low-level exercise, patients with HFpEF demonstrated greater relative increases in VC, coupled with heightened ventilatory drive and more severe symptoms of dyspnea compared with control subjects. At 20-W exercise, DM was markedly reduced in patients with HFpEF compared with control subjects. From 20 W to peak exercise, there was no further increase in VC in patients with HFpEF, which in tandem with reduced DM, led to a 30% reduction in DLCO at peak exercise (17.3 ± 4.2 ml/mm Hg/min vs. 24.7 ± 7.1 ml/mm Hg/min; p < 0.01).
Conclusions:
Subjects with HFpEF display altered pulmonary function and gas exchange at rest and especially during exercise, which contributes to exercise intolerance. Novel therapies that improve gas diffusion may be effective to improve exercise tolerance in patients with HFpEF.
Introduction
Elevation in pulmonary venous pressures with exercise is pathognomonic of heart failure with preserved ejection fraction (HFpEF) (1). Many studies have examined the hemodynamic mechanisms underlying filling pressure elevation in HFpEF (2–4), but very little is known about how these mechanisms might alter pulmonary gas exchange and ventilatory mechanics to produce dyspnea. It is important to understand how the hemodynamic abnormalities that develop during exercise in HFpEF affect the alveolar-pulmonary capillary interface so novel therapeutics can be designed.
Acute elevation in pulmonary venous pressure can cause interstitial or alveolar edema, whereas sustained increases can cause pulmonary vascular remodeling (5). Increases in venous pressure during exercise in HFpEF may alter forces that govern fluid distribution between the vascular, capillary wall, and alveolar spaces in the lung, which potentially results in interstitial edema, impaired gas conductance, stiffer lungs, a more tachypneic pattern of breathing, and greater ventilatory drive and ventilatory inefficiency, all of which may increase the work and cost of breathing, and heighten symptoms of dyspnea during exercise (6).
The aim of this study was to comprehensively examine the pulmonary response to exercise in HFpEF by assessing measures of gas exchange, ventilatory drive and efficiency, and the diffusion capacity of the lungs for carbon monoxide (DLCO) and its subcomponents (pulmonary capillary blood volume [VC] and alveolar-capillary membrane conductance [DM]) in subjects with HFpEF compared with healthy control subjects at rest and during exercise. We hypothesized that subjects with HFpEF would demonstrate reduced lung diffusion at rest and with exercise related to distinct patterns of change in capillary blood volume and membrane conductance.
Methods
Patients with HFpEF (n = 20) with EF >50% and unequivocal signs and symptoms of heart failure (Framingham criteria) were studied prospectively in as outpatients and were compensated for the study. Exclusion criteria included significant valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, obstructive or restrictive pulmonary disease, unstable coronary disease, atrial fibrillation, pregnancy, primary renal or hepatic disease, and inability to exercise or to suspend cardiovascular medicines. Healthy control subjects without cardiovascular disease or diabetes (n = 26) were recruited by advertisement.
Some clinical characteristics, cardiovascular function, and exercise capacity data from subjects in this study have previously been published (7); however, none of the data on pulmonary diffusion capacity, its subcomponents, or the relationships presented in this paper have been reported. All participants gave written informed consent after being provided a description of study requirements. The protocol was approved by the Mayo Clinic Institutional Review Board, and all procedures conformed to the Declaration of Helsinki. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the paper as written.
Exercise testing protocol
Subjects were instructed to avoid strenuous physical activity for 24 hours before arrival and were studied in the upright position in an ambulatory, compensated, fasting state in a quiet, temperature-controlled room (21°C). In addition, all cardiovascular medicines were withheld for 24 h before study. Ventilatory, gas exchange, heart rate, and oxygen saturation data were measured continuously during exercise.
Exercise testing was conducted on a recumbent electronically braked cycle ergometer (Corival, Lode Medical Technology, Groningen, the Netherlands). The exercise protocol consisted of pedaling at a constant cadence of 65 rpm with an initial resistance of 0 W that was subsequently increased every 3 min by 20 W. Symptoms of fatigue were quantified by the rating of perceived exertion (RPE) on the Borg 6 to 20 scale. Subjects were verbally encouraged to continue the exercise protocol to maximal exertion, identified by RPE ≥17. Symptoms of dyspnea were quantified by the Borg dyspnea score (0 to 10). Brachial blood pressure (BP) was obtained by auscultation by a single investigator during rest and at the end of each stage of exercise.
Ventilation and expired gas analysis
Breath-by-breath oxygen consumption (VO2), carbon dioxide production (VCO2), minute ventilation (VE), tidal volume (VT), breathing frequency (fb), inspiratory time (TI), and total respiratory cycle time (TTOT) were measured continuously via a metabolic measurement system through a mouth piece and pneumotachograph while wearing a nose clip (CPX/D, Medical Graphic, St. Paul, Minnesota). Manual volume calibration was performed with a 3-L syringe, and gas calibration was performed with manufacturer-recommended gases of known concentration. All calibration procedures were conducted immediately before each testing protocol.
Aerobic capacity was assessed by the peak VO2 attained during exercise. Objective exercise effort was assessed by the peak respiratory exchange ratio (VCO2/VO2). Ventilatory efficiency was assessed by the slope of VE to VCO2, and ventilatory drive was assessed by the ratio of VT to TI (8). All analyses of ventilation and gas exchange data were conducted offline in a blinded fashion.
Pulmonary diffusing capacity and subcomponents
The disappearance of carbon monoxide in concert with nitric oxide was measured for the assessment of DM and VC as previously described in detail (9–11). Briefly, measurement of the DLCO and diffusing capacity of the lungs for nitric oxide (NO) was conducted using the rebreathing technique, with gases sampled on a mass spectrometer (Perkin-Elmer 1100, Perkin-Elmer, St. Louis, Missouri) and NO analyzer (Sievers Instruments, Boulder, Colorado) using a custom analysis software package (9,11). A 5-L rebreathe bag was filled with 0.3% carbon monoxide (C18O), 40-ppm NO (diluted immediately before each measurement in the rebreathe bag from an 800-ppm gas mixture), 35% oxygen, and balanced nitrogen. The isotope C18O was used in place of the more common C16O as the test gas because the molecular mass of C16O is nearly identical to that of balanced nitrogen, making these gases indistinguishable by the mass spectrometer (9,11).
The volume of gas used to fill the rebreathe bag was determined by the VT of the subject. Consistent bag volumes were ensured by using a timed switching circuit that, given a consistent flow rate from the tank, resulted in the desired volume. For each maneuver, subjects were switched to the rebreathe bag at the end of a normal expiration (end-expiratory lung volume) and instructed to nearly empty the bag with each breath for 10 consecutive breaths. The fb during the rebreathe maneuver was controlled with a metronome at a rate of 32 breaths/min unless the intrinsic frequency was >32 breaths/min, at which time the metronome was switched off. The rebreathe bag was then emptied with a suction device and refilled immediately before the next maneuver. All analyses of pulmonary diffusion and its subcomponents were conducted offline in a blinded fashion.
Measurement of cardiac output
Transthoracic echocardiography was used to measure stroke volume from the left ventricular (LV) outflow dimension and pulse wave Doppler as previously described (7). Stroke volume was multiplied by heart rate to calculate cardiac output. Echo-Doppler measurements were interpreted offline in a blinded fashion and represent the mean of ≥3 consecutive beats collected by a trained cardiac sonographer.
Statistical analysis
Continuous variables are reported as mean ± SD. Between-group differences were compared by the chi-square test for categorical variables, analysis of variance for normally-distributed continuous variables, and by Wilcoxon rank sum or Kruskal-Wallis tests for non-normally distributed continuous variables. Normality was evaluated for each variable by the Shapiro-Wilk W test. Bonferroni correction was applied for multiple comparisons. Bivariate (Pearson’s coefficient) linear regression was performed to test associations between diffusing capacity of the lungs and its subcomponents and peak exercise capacity, ventilatory drive, and symptomology during exercise. Because patients with HFpEF reach lower exercise workload on average than subjects without HF, comparisons were made at both matched, low-level workload (20 W), and at peak exercise. All statistical analyses were performed using SPSS version 20.0 (IBM, Armonk, New York), with graphical representation using GraphPad Prism 6 (GraphPad Software, La Jolla, California).
Results
Subject characteristics
Subject characteristics
Patients with HFpEF had higher body mass than control subjects, but age, sex, comorbidity burden, and renal function were similar in the 2 groups (Table 1). Patients with HFpEF reported New York Heart Association functional class II to III symptoms and displayed elevated B-type natriuretic peptide levels along with higher left atrial volume and greater early mitral inflow velocity/medial mitral annular velocity ratios, which were all consistent with elevated LV filling pressures. LV mass was higher in patients with HFpEF, whereas EF, heart rate, and BP were similar in HFpEF and control subjects. None of the subjects were treated with amiodarone or had sleep-disordered breathing.
Control (n = 26) | HFpEF (n = 20) | p Value | |
---|---|---|---|
Clinical characteristics | |||
Age (yrs) | 65 ± 9 | 67 ± 11 | 0.4 |
Sex (% female) | 69 | 75 | 0.7 |
Body mass index (kg/m2) | 29.1 ± 5.5 | 34.5 ± 6.8 | 0.004 |
NYHA functional class I/II/III | 26/0/0 | 0/9/11 | <0.0001 |
Hypertension (%) | 62 | 85 | 0.11 |
Smoking history (%) | 0 | 10 | 0.18 |
eGFR (ml/min) | 80 ± 18 | 82 ± 39 | 0.8 |
Plasma BNP (pg/ml) | 37 (16–61) | 175 (58–200) | 0.0003 |
Hemoglobin (g/dl) | 14.0 ± 1.8 | 13.1 ± 1.3 | 0.08 |
Loop diuretic agent (%) | 0 | 60 | 0.0005 |
Resting hemodynamics and echocardiography | |||
Heart rate (beats/min) | 70 ± 11 | 68 ± 13 | 0.7 |
Systolic BP (mm Hg) | 133 ± 15 | 129 ± 20 | 0.4 |
LV mass index (mg/m2) | 82 ± 24 | 87 ± 27 | 0.5 |
Ejection fraction (%) | 58 ± 5 | 60 ± 6 | 0.2 |
LA volume index (ml/m2) | 31 ± 7 | 45 ± 14 | 0.0001 |
E/E′ ratio | 11 ± 4 | 20 ± 8 | 0.0004 |
Cardiac index (l/min*m2) | 2.3 ± 0.6 | 2.3 ± 0.6 | 0.6 |
Exercise performance
Exercise time, peak workload, VO2 at ventilatory threshold, peak VO2, and percent predicted peak VO2 were all markedly impaired in patients with HFpEF compared with control subjects (Table 2). Borg effort and dyspnea scores in HFpEF subjects were higher at matched submaximal workload (20 W), which indicated greater perceived difficulty with low-level exercise at matched workload (Figure 1). At peak, Borg scores were similar between patients with HFpEF and control subjects, which was consistent with maximal subjective effort in all groups, but Borg scores relative to work performed were higher in patients with HFpEF. There was no difference in the peak respiratory exchange ratio between the patients with HFpEF and control subjects.
Control Values (n = 26) | HFpEF (n = 20) | p Value | |
---|---|---|---|
Exercise time (s) | 840 ± 239 | 495 ± 210 | <0.001 |
Peak workload (W) | 93 ± 27 | 55 ± 23 | <0.001 |
Peak VO2 (ml/kg/min) | 18.6 ± 3.3 | 12.7 ± 3.2 | <0.001 |
% Predicted peak VO2 (%) | 94 ± 22 | 57 ± 19 | <0.001 |
Peak respiratory exchange ratio | 1.09 ± 0.07 | 1.05 ± 0.09 | 0.11 |
VO2 at VAT (ml/kg/min) | 14.2 ± 2.5 | 10.4 ± 2.3 | <0.001 |
VE/VCO2 slope | 33.5 ± 3.0 | 36.0. ± 5.0 | 0.05 |
20-W Borg effort (6–20) | 8.6 ± 1.4 | 11.3 ± 2.4 | <0.001 |
20-W Borg dyspnea (0–10) | 0.8 ± 0.7 | 2.8 ± 1.5 | <0.001 |
Peak Borg effort (6–20) | 16.2 ± 1.8 | 15.7 ± 2.2 | 0.45 |
Peak Borg dyspnea (0–10) | 5.2 ± 1.9 | 5.5 ± 2.0 | 0.61 |
Ventilation, gas exchange, and lung diffusion at rest and during exercise
There were no differences in VO2 or measures of ventilation and breathing pattern at rest (Table 3). In contrast, DLCO was significantly lower in the patients with HFpEF compared with control subjects. Compared with control subjects, patients with HFpEF displayed lower DM, which reflected impaired membrane gas transfer, along with lower VC, which reflected pulmonary capillary oligemia despite evidence of higher left heart filling pressures, as noted previously (Table 3, Figure 2).
Controls (n = 26) | HFpEF (n = 20) | p Value | |
---|---|---|---|
Rest | |||
VO2 (ml/kg/min) | 3.60 ± 0.51 | 3.29 ± 0.82 | 0.13 |
Q (l/min) | 4.4 ± 1.2 | 4.9 ± 1.2 | 0.15 |
SV (ml/beat) | 63.9 ± 17.6 | 74.1 ± 20.9 | 0.09 |
HR (beats/min) | 70 ± 11 | 68 ± 13 | 0.7 |
VE (l/min) | 8.5 ± 1.9 | 9.5 ± 2.4 | 0.14 |
fb (breaths/min) | 14 ± 3 | 15 ± 4 | 0.5 |
VT (ml) | 615 ± 166 | 655 ± 218 | 0.5 |
VE/VCO2 (ratio) | 38.6 ± 5.0 | 40.1 ± 6.4 | 0.4 |
VT/TI (ratio) | 448 ± 120 | 547 ± 122 | 0.01 |
DLCO (ml/mm Hg/min) | 14.4 ± 3.3 | 11.0 ± 2.3 | <0.001 |
DM (ml/mm Hg/min) | 23.1 ± 9.1 | 18.1 ± 4.9 | 0.04 |
VC (ml) | 58.9 ± 16.2 | 45.9 ± 15.2 | 0.01 |
Matched workload (20 W) | |||
VO2 (ml/kg/min) | 9.6 ± 1.2 | 8.9 ± 1.41 | 0.06 |
Q (l/min) | 8.2 ± 2.3 | 7.2 ± 1.4 | 0.12 |
SV (ml/beat) | 86.2 ± 21.7 | 77.8 ± 19.1 | 0.09 |
HR (beats/min) | 85 ± 17 | 94 ± 15 | 0.04 |
VE (l/min) | 20.1 ± 4.4 | 24.0 ± 5.3 | 0.01 |
fb (breaths/min) | 23 ± 4 | 28 ± 8 | 0.02 |
VT (ml) | 883 ± 197 | 876 ± 188 | 0.9 |
VE/VCO2 (ratio) | 34.3 ± 4.2 | 36.0 ± 5.0 | 0.2 |
VT/TI (ratio) | 922 ± 225 | 1,133 ± 340 | 0.02 |
DLCO (ml/mm Hg/min) | 17.4 ± 3.6 | 14.5 ± 4.0 | 0.01 |
DM (ml/mm Hg/min) | 26.9 ± 6.6 | 21.5 ± 6.1 | 0.008 |
VC (ml) | 67.6 ± 23.3 | 64.9 ± 24.9 | 0.7 |
Peak exercise | |||
VO2 (ml/kg/min) | 18.6 ± 3.3 | 12.7 ± 3.2 | <0.001 |
Q (l/min) | 13.2 ± 3.7 | 9.2 ± 2.5 | 0.004 |
SV (ml/beat) | 91.6 ± 22.1 | 80.0 ± 25.1 | 0.11 |
HR (beats/min) | 144 ± 20 | 119 ± 22 | <0.001 |
VE (l/min) | 56.7 ± 14.3 | 42.9 ± 12.4 | 0.002 |
fb (breaths/min) | 37 ± 6 | 36 ± 9 | 0.9 |
VT (ml) | 1,570 ± 433 | 1,206 ± 344 | 0.005 |
VE/VCO2 (ratio) | 34.5 ± 3.6 | 37.1 ± 4.7 | 0.05 |
VT/TI (ratio) | 2,273 ± 560 | 1,864 ± 452 | 0.01 |
DLCO (ml/mm Hg/min) | 24.7 ± 7.1 | 17.3 ± 4.2 | <0.001 |
DM (ml/mm Hg/min) | 39.6 ± 12.9 | 27.2 ± 6.3 | 0.001 |
VC (ml) | 86.1 ± 24.3 | 66.4 ± 24.9 | 0.01 |
During matched submaximal workload (20 W), VO2 tended to be lower in the patients with HFpEF (p = 0.06) (Table 3). The DLCO was lower in the HFpEF group compared with control subjects at 20 W, which was mediated exclusively by reduced DM (Table 3). Notably, VC increased dramatically from baseline in the HFpEF group to 20-W exercise to a level that was not different from control subjects (Figure 2). Despite lower absolute values in patients with HFpEF, relative changes in DLCO and DM from rest to 20-W exercise were similar in patients with HFpEF and control subjects. In contrast, the relative change in VC was 2-fold greater in patients with HFpEF than control subjects during low-level exercise (Figure 3A). This greater increase in VC at 20 W was coupled with higher VE and VT/TI (index of ventilatory drive) in the HFpEF group compared with the control group (Table 3). The increase in VE in HFpEF was due to higher fb, with no difference in VT, indicating a more tachypneic breathing pattern (Figure 1).
At peak exercise, VE was lower in the HFpEF group compared with the control group, mediated by reduced VT (Table 3). However, relative to the work performed, VT responses were similar in the 2 groups, whereas fb was persistently elevated in HFpEF relative to exercise workload (Figure 1). The DLCO during peak exercise in patients with HFpEF was again lower compared with the control subjects, as a function of both a reduction in DM and VC (Table 3, Figure 2). From 20-W exercise up to peak, there was proportionately greater increase in DLCO, DM, and VC in control subjects compared with patients with HFpEF (Figure 3B). Notably, there was no further increase in VC from 20 W to peak exercise in patients with HFpEF, indicating that pulmonary capillary blood volume reserve became saturated during low-level exercise.
At any cardiac output, absolute DLCO and DM values were consistently lower in patients with HFpEF than control subjects, whereas VC was lower in patients with HFpEF only at baseline and peak exercise (Figure 2). Peak VO2 was directly correlated with exercise increases in DLCO (r = 0.68; p < 0.0001) and DM (r = 0.69; p < 0.0001). In contrast, peak VO2 was only modestly associated with changes in VC (r = 0.33; p = 0.02).
Discussion
This prospective study is the first to evaluate pulmonary gas diffusion both at rest and during exercise in patients with HFpEF, with separation of individual determinants of gas transfer, including DM and VC. We demonstrate that patients with HFpEF have important limitations to gas transfer as evidenced by a global reduction in DLCO, both at rest and during exercise. Examination of the individual determinants of lung diffusion reveals a complex and dynamic interplay; with the onset of low-level exercise, there is a greater increase in VC in patients with HFpEF compared with that of control subjects, which is presumably related to the greater increase in pulmonary venous pressures. Despite the greater rise in VC with low-level exercise in patients with HFpEF, DLCO remains lower than that in control subjects because of persistently decreased DM. From low level to peak exercise, there is no further increase in VC in patients with HFpEF, in contrast to the steady increases in VC with increasing cardiac output observed in control subjects. This indicates a limitation in pulmonary vascular recruitment with maximal exercise, which coupled with impaired DM, greatly limits gas transfer during exercise in patients with HFpEF. Diffusion abnormalities in HFpEF were associated with lower aerobic capacity and were coupled to greater symptoms of dyspnea, more profound tachypnea, and increased ventilatory drive relative to exercise workload. These data provide new insight into the mechanisms by which hemodynamic abnormalities developing during exercise in subjects with HFpEF alter pulmonary function and gas exchange to contribute to symptoms of exercise intolerance. Novel therapies that improve gas diffusion through either hemodynamic or non-hemodynamic mechanisms may be effective to improve exercise tolerance in subjects with HFpEF.
Determinants of pulmonary diffusing capacity
DLCO describes the conductance of gas from the alveolus across the alveolar-capillary membrane to bind hemoglobin in erythrocytes (9). The reciprocal of this conductance (1/DLCO) thus represents the total resistance to gas transfer in the lungs and is determined by the sum of resistances imposed by the 1/DM and 1/θ ⋅ VC (9,12). Previous studies in patients with HF and reduced EF (HFrEF) have shown that DLCO and DM are reduced compared with that in control subjects when measured at rest, and that the extent of this impairment is correlated with a greater burden of pulmonary vascular disease, worse ventilatory inefficiency, greater HF severity, lower exercise capacity, and increased mortality (13–16). The present results show that these limitations in resting gas diffusion are also present in patients with HFpEF, and that the extent of these limitations is associated with impaired exercise capacity, hyperpnea, and symptoms of dyspnea.
Pulmonary diffusion reserve in heart failure
In the normal alveolar-capillary interface, DLCO increases linearly with cardiac output during exercise. This is typically attributed to increased DM and VC due to capillary and alveolar distention and recruitment, which results in increased surface area available for gas exchange, along with more homogenous distribution of red cells within and among the pulmonary capillaries (17). Previous studies in HFrEF patients have evaluated changes in global gas diffusion (DLCO) during exercise. Smith et al. (18) found that the increase in DLCO relative to cardiac output was impaired in patients with HFrEF during low-level exercise (30 W). Olson et al. (19) later confirmed and extended this observation, showing reduced DLCO both at low level and peak exercise in patients with HFrEF. The present results in HFpEF reveal a similar picture, with impaired recruitment of pulmonary gas diffusion reserve during exercise in patients with HFpEF compared with that in control subjects.
The primary novel finding in the present study is the evaluation of the individual determinants of lung diffusion during exercise, which has not been studied to date in any HF population. Agostoni et al. (15) examined DLCO, DM, and VC at baseline and then 2 min following exercise in patients with HFrEF and control subjects. The investigators observed that although VC increased after exercise in patients with HFrEF, DM decreased, which was consistent with the development of interstitial pulmonary edema. Similar reductions in DM have been observed following acute saline infusion in patients with HFrEF (13,14).
In contrast, the present study did not observe a reduction in DM during exercise, although absolute values of DM were lower in patients with HFpEF compared with control subjects for any given workload. The reason for the discrepant results may relate to the timing of DM assessment, which was during exercise in the present study, as opposed to after exercise had been completed in the study of Agostoni et al. (15). Following cessation of exercise, many of the factors that dictate recruitment of DM (e.g., distention of alveolar septae from increased ventilation, opening of capillaries with increased cardiac output) are no longer present. The slope of increase in DM relative to cardiac output was similar in cases and control subjects (Figure 2), which argues against the development of interstitial pulmonary edema during exercise in in patients with HFpEF, despite a greater increase in VC with submaximal exercise (Figures 2 and 3). It may be that chronic remodeling of the alveolar-capillary membrane protects against the development of interstitial edema during transient increases in pulmonary venous pressure during exercise in patients with HFpEF, but at the cost of impediment to gas transfer at the membrane (i.e., lower DM) (20,21). Cardiac output reserve was depressed in patients with HFpEF, and it cannot be determined from these data whether DM and VC responses to exercise might have differed if cardiac output were closer to normal.
Changes in pulmonary capillary blood volume during exercise in HFpEF
Reduction in exercise capacity in many patients with HFpEF is determined largely by inadequate cardiac output reserve, which, when coupled with stress-induced elevations in pulmonary venous pressures, markedly limits exercise capacity (1,4,22). In this light, we can envision a setting where the decrements in cardiac reserve, coupled with elevated filling pressures, would exacerbate hemodynamic pooling in the pulmonary circulation. This theoretical construct is supported by the present study, which demonstrates a greater increase in VC from rest to a low intensity workload (20 W) in patients with HFpEF. This rapid rise during the onset of exercise corresponds to the time when the largest increase in left heart filling pressures is observed in patients with HFpEF (1,23). Eighty percent of the total increase in pulmonary venous pressure that will occur during exercise in patients with HFpEF is observed in the first 1.5 min of exercise at 20 W (1). We speculate that increases in venous return in this early stage cannot be accommodated by the left ventricle in HFpEF because of diastolic reserve limitation (4), such that during onset of exercise, right ventricular output transiently exceeds left ventricular output, and thus, blood pools in the pulmonary circulation. This is consistent with the greater relative increase in VC in the patients with HFpEF observed at 20 W. With higher levels of exercise, a new steady state may be reached in patients with HFpEF, where left- and right-sided cardiac outputs are matched, even as they both remain lower than what is observed in control subjects, as in the present study and others (22). Alternatively, it may simply be that the ability to recruit greater pulmonary capillary volume becomes rapidly saturated in HFpEF during low-level exercise due to vascular remodeling.
Study limitations
Body mass index was greater in the patients with HFpEF compared with control subjects, although this seems unlikely to influence gas diffusion in the lungs, because lung size does not vary with body composition. Invasive LV filling pressures were not assessed as part of this study, but are well known to increase dramatically during exercise in patients with HFpEF, and measures reflective of resting LV filling pressures (B-type natriuretic peptide, early mitral inflow velocity/medial mitral annular velocity, left atrial volume) were all increased in patients with HFpEF compared with control subjects. Future study is required to clarify how hemodynamic derangements relate to observed changes in gas diffusion in HFpEF. Control subjects in the present study displayed somewhat depressed exercise capacity and mild ventilatory inefficiency. However, all were recruited a priori based upon the absence of known cardiovascular disease, and the mildly abnormal exercise findings in this group would only bias any observed group differences toward the null. Right ventricular function is known to be abnormal in HFpEF, but it was not assessed in the present study (24).
Conclusions
The results of this study confirm our hypothesis that patients with HFpEF demonstrate significant reductions in pulmonary gas diffusion capacity during exercise compared with healthy control subjects. The impairment of DLCO reserve is related to abnormalities in DM and VC, which vary as a function of exercise intensity with persistent depression in DM throughout exercise. This is presumably related to alveolar-capillary remodeling, with a greater increase in VC early during exercise, followed by a failure to increase VC, which further reflects deficits in vascular recruitment reserve. These data provide important new insights into the pulmonary effects of hemodynamic abnormalities that develop during exercise in HFpEF, and demonstrate that patients with HFpEF have impaired lung diffusion both at rest and during graded exercise that is related to abnormalities in lung conductance and capillary blood volume. Further study is warranted to determine how these abnormalities in lung diffusion might be targeted therapeutically to improve exercise capacity and tolerance in patients with HFpEF.
COMPETENCY IN MEDICAL KNOWLEDGE 1: Patients with HFpEF display abnormal pulmonary gas transfer at rest that is related to abnormalities in lung membrane conductance and pulmonary capillary oligemia, despite evidence of elevated filling pressures.
COMPETENCY IN MEDICAL KNOWLEDGE 2: With low-level exercise, when filling pressures increase dramatically, there is a greater increase in pulmonary capillary blood volume in HFpEF that is coupled to increased ventilatory drive and greater symptoms of dyspnea.
COMPETENCY IN MEDICAL KNOWLEDGE 3: Up to maximum exercise, there is persistently impaired gas transfer related to reduced membrane conductance and inability to further recruit the pulmonary capillary vasculature in HFpEF.
TRANSLATIONAL OUTLOOK 1: Novel therapies that target pulmonary gas transfer, through either hemodynamic or non-hemodynamic mechanisms, may help improve exercise tolerance in patients with HFpEF.
1. : "Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction". Circ Heart Fail 2010; 3: 588.
2. : "Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle". N Engl J Med 2004; 350: 1953.
3. : "Role of left ventricular stiffness in heart failure with normal ejection fraction". Circulation 2008; 117: 2051.
4. : "Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction". Heart 2011; 97: 964.
5. : "Pulmonary hypertension due to left heart disease". Circulation 2012; 126: 975.
6. : "Exercise-disordered breathing in chronic heart failure". Exerc Sport Sci Rev 2006; 34: 194.
7. : "Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction". J Am Coll Cardiol 2010; 56: 845.
8. : "Breathing pattern and lung volumes during exercise". Acta Physiol Scand 1984; 120: 123.
9. : "Calculating alveolar capillary conductance and pulmonary capillary blood volume: comparing the multiple- and single-inspired oxygen tension methods". J Appl Physiol 2010; 109: 643.
10. : "Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in health humans". Eur J Appl Physiol 2008; 103: 421.
11. : "Pulmonary membrane diffusing capacity and capillary blood volume measured during exercise from nitric oxide uptake". Chest 2001; 120: 1850.
12. : "Apparent pulmonary diffusing capacity for CO at varying alveolar O2 tensions". J Appl Physiol 1957; 11: 277.
13. : "Impeded alveolar-capillary gas transfer with saline infusion in heart failure". Hypertension 1999; 34: 1202.
14. : "Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction". Circulation 1999; 99: 1190.
15. : "Exercise-induced pulmonary edema in heart failure". Circulation 2003; 108: 2666.
16. : "Alveolar-capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure". Eur Heart J 2002; 23: 467.
17. : "Reference values of pulmonary diffusion capacity during exercise by a rebreathing technique". Am J Rep Crit Care Med 1995; 152: 658.
18. : "Impaired pulmonary diffusion during exercise in patients with chronic heart failure". Circulation 1999; 100: 1406.
19. : "Reduced rate of alveolar-capillary recruitment and fall of pulmonary diffusing capacity during exercise in patients with heart failure". J Card Fail 2006; 12: 299.
20. : "Pulmonary microvascular permeability: responses to high vascular pressure after induction of pacing-induced heart failure in dogs". Circ Res 1995; 77: 317.
21. : "Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema". Jpn Circ J 1979; 43: 945.
22. : "Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction". Eur J Heart Fail 2013; 15: 776.
23. : "Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction". J Am Coll Cardiol 2010; 56: 855.
24. : "Right heart dysfunction in heart failure with preserved ejection fraction". Eur Heart J 2014; 35: 3452.
Abbreviations and Acronyms
BP | blood pressure |
DLCO | diffusion of the lungs for carbon monoxide |
DM | alveolar-capillary membrane conductance |
EF | ejection fraction |
fb | breathing frequency |
HFpEF | heart failure with preserved ejection fraction |
HFrEF | heart failure with reduced ejection fraction |
LV | left ventricle |
NO | nitric oxide |
RPE | rating of perceived exertion |
TI | inspiratory time |
TTOT | total respiratory cycle time |
VC | pulmonary capillary blood volume |
VCO2 | volume of carbon dioxide produced |
VE | minute ventilation |
VO2 | volume of oxygen consumed |
VT | tidal volume |
Footnotes
Dr. Olson was supported by a grant from the American Heart Association (AHA-12GRNT11630027). Dr. Johnson was supported by NIH grant HL71478. Dr. Borlaug was supported by grants from the Mayo Clinic CTSA, NIH (UL RR024150), and the Marie Ingalls Career Development Award in Cardiovascular Research.